Combs Stephanie E, Kelter Verena, Welzel Thomas, Behnisch Wolfgang, Kulozik Andreas E, Bischof Marc, Hof Holger, Debus Jürgen, Schulz-Ertner Daniela
Neuro-Radiation Oncology Research Group, Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):972-8. doi: 10.1016/j.ijrobp.2007.12.036. Epub 2008 Mar 11.
To assess the outcome of 57 patients with localized ependymomas treated with radiotherapy (RT).
Fifty-seven patients with localized ependymomas were treated with RT. Histology was myxopapillary ependymoma (n = 4), ependymoma (n = 23), and anaplastic ependymoma (n = 30). In 16 patients, irradiation of the craniospinal axis (CSI) was performed with a median dose of 20 Gy. Forty-one patients were treated with local RT, with a local dose of 45 Gy to the posterior fossa, including a boost to the tumor bed of 9 Gy. In 19 patients, the tumor bed was irradiated with a median dose of 54 Gy.
Overall survival after primary diagnosis was 83% and 71% at 3 and 5 years. Five-year overall survival was 80% in low-grade and 79% in high-grade tumors. Survival from RT was 79% at 3 and 64% at 5 years. We could not show a significant difference in overall survival between CSI and local RT only. Freedom of local failure was 67% at 5 years in patients treated with CSI and 60% at 5 years after local RT. A rate of 83% for distant failure-free survival could be observed in the CSI group as opposed to 93% in the group receiving local RT only.
Local RT in patients with localized tumors is equieffective to CSI. The radiation oncologist must keep in mind that patients with localized ependymomas benefit from local doses > or =45 Gy.
评估57例接受放射治疗(RT)的局限性室管膜瘤患者的治疗结果。
57例局限性室管膜瘤患者接受了RT治疗。组织学类型为黏液乳头型室管膜瘤(n = 4)、室管膜瘤(n = 23)和间变性室管膜瘤(n = 30)。16例患者进行了全脑全脊髓轴照射(CSI),中位剂量为20 Gy。41例患者接受局部RT治疗,后颅窝局部剂量为45 Gy,包括对肿瘤床追加9 Gy的剂量。19例患者肿瘤床的照射中位剂量为54 Gy。
初次诊断后的总生存率在3年和5年时分别为83%和71%。低级别肿瘤的5年总生存率为80%,高级别肿瘤为79%。RT后的生存率在3年时为79%,5年时为64%。我们未能显示仅CSI和局部RT之间在总生存率上有显著差异。接受CSI治疗的患者5年局部无复发生存率为67%,局部RT后5年为60%。CSI组远处无复发生存率为83%,而仅接受局部RT治疗的组为93%。
局限性肿瘤患者的局部RT与CSI疗效相当。放射肿瘤学家必须牢记,局限性室管膜瘤患者从局部剂量≥45 Gy中获益。